Oncolytics Biotech Inc ONCY

Merck to buy Prometheus Bio....

[fox7mf]

...for an all cash deal worth $10.8b usd. Prometheus is currently trading at $115usd, so I guess shareholders can expect to receive $230usd per share, considering the 47.3 million outstanding shares. Similar math would see Oncy receive a buyout offer of $2.30usd per share, considering their current SP. What a sincerely pathetic situation we shareholders find ourselves in. Great job BOD!!!

[TMAZZ21]

Such a great job that they have the nerve to ask for more options.

[venture009]

Fox, I share your frustration. Like you I have been invested in this stock for far to long (23 years). The valuation and the retail interest in this stock has always been a concern, especially when they post, what seem to be break throughs on cancers like breast, pancreatic cancer and possibly colon. None of these results have attracted new retail investors nor a partner. Why? Is it because the

[westcoast1000]

Venture009, With respect, you stringing together disappointments and lumping things together that do not make sense. The sample sizes of all our trials are driven by cost and the difficulty of getting participants, as well as the purpose of the trials at that stage. The sample sizes were set large enough to accomplish the purposes of the trials, and approved by regulators. Even with large sample

[venture009]

Westcoast,  for the panc trials the investgators said they did not have trouble recruiting candidates so this wasn't the reason for the smal number, which is not statistical significant. If you look at other small biotechs the vast majority will have minimum of 50 trial participants. Nevertheless, after 20+ years this company has not been able to attract a partner let alone a buyout and

[Noteable]

Covid-19 negatively impacted patient enrollment for every company iwho was nterested in conducting clinical studies for 2 years starting in 2020 and continuing until late 2022, including ONCY. This negative impact still continues and study size numbers have since adjusted downwards in response. https://www.clinicaltrialsarena.com/comment/slow-recruitment-covid-19-disruptions/

[Noteable]

Because of COVID-19 companies had to delay the initiation of planned trials or withdraw them completely, suspend enrolment in ongoing trials or terminate those trials altogether.

[westcoast1000]

 "the investgators said they did not have trouble recruiting candidates so this wasn't the reason for the smal number, which is not statistical significant." Are you referring to the Goblet trials? We do not yet have results on PFS or OS. Those come after everyone on the trial progresses.  Whether the results are statistically significant cannot be answered without the

[westcoast1000]

Further to my previous message: The statistical test to be used is likely the difference in the medians (means would be easier) over the variance. The medians would likely be the result of this arm compared to the standard of care outcome for that arm. If there is very little variance, then the number is bigger. I cannot eyeball the variance from what is shown on the ONCY web site. But if there

[Lesalpes29]

All good comments from you Westcoast. Thank you for your work and good writing. I can understand almost everything! For some here like me, the frustrations are coming probably from how they play the game right now. No NR for months as a result the SP is probably manipulated down and ask during that time a bunch of new very cheap options. Still believe a deal will come this year and will not sell

[KTDfyi]

It's nice to read a well written summary of the company. The most important thing people need to understand is that science progresses. Without the research into checkpoint blockade and car t the company wouldn't be in the position they are today. So, ya, oncy was able to piggyback on others research to get to the point whereby they are now able to produce meaningful positive results for

[Buckhenry]

The pumping dreamers get more desperate  with each day and stupid post....